Dr. Kass on Testing for HER2-Positive Breast Cancer

Fred C. Kass, MD
Published: Monday, Jul 20, 2015



Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Kass explains that fluorescence in situ hybridization (FISH) is preferred in the oncology community versus immunohistochemistry (IHC)upfront. IHC is only used first, he adds, when the FISH results are unequivocal. If both FISH and IHC results are equivocal, then oncologists send specimens to a reference lab.

Oncologists concur that testing patients with FISH first is more reliable method, Kass says.

SELECTED
LANGUAGE


Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Kass explains that fluorescence in situ hybridization (FISH) is preferred in the oncology community versus immunohistochemistry (IHC)upfront. IHC is only used first, he adds, when the FISH results are unequivocal. If both FISH and IHC results are equivocal, then oncologists send specimens to a reference lab.

Oncologists concur that testing patients with FISH first is more reliable method, Kass says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x